Polymyositis News

The prevalence of neuropsychiatric symptoms in patients with systemic autoimmune rheumatic diseases is significantly “higher and more wide-ranging” than previously recognized, according to data published in Rheumatology.

SAN DIEGO — Imaging and symptom rating scales offer physicians ample opportunity to follow patients with suspected myositis and “tease out” fast vs. slow progressors, noted a speaker at the 2023 Congress of Clinical Rheumatology West.

Properly managing cardiovascular disease in patients with immune-mediated inflammatory diseases requires following guidelines and inter-specialty collaboration, according to a speaker at the Biologic Therapies Summit.

The FDA has granted an investigational new drug application for CABA-201, a 4-1BB-containing fully human CD19-CAR T-cell therapy, to be studied in patients with myositis, according to a press release from the manufacturer.

DESTIN, Fla. — Understanding which autoantibodies are present in patients with myositis can help with both diagnosis and treatment, according to a presenter at the 2023 Congress of Clinical Rheumatology-East.

DESTIN, Fla. — Although new targets and therapies are on the horizon, current myositis treatment strategies rely on treating impacted organ groups, according to a speaker at the 2023 Congress of Clinical Rheumatology-East.

The recent FDA approval of sarilumab for the treatment of refractory polymyalgia rheumatica may have a significant and lasting impact on the use of long-term steroids for that condition.

Leaders of the U.S. Senate Finance Committee have introduced a bipartisan framework aimed at regulating pharmacy benefit managers as well as to “modernize and enhance” federal prescription drug programs, according to a press release.

Approximately 74% of YouTube videos on myositis provide useful information, with nearly half of useful videos created by professional medical societies or patient support groups, according to data published in Clinical Rheumatology.

Conventional memory B cells with low CXCR5 levels and CXCR5 T-helper 2 memory cells are potential biomarkers of juvenile dermatomyositis disease activity, according to data published in Arthritis & Rheumatology.